In the future, the pharmaceutical industry will integrate AI into drug design, making it an essential tool for biology and chemistry.

The advancements in AI, such as AlphaFold, are revolutionizing fields like medicine, enabling us to design proteins that can potentially cure diseases like cancer.

By 2050, we envision a fully automated lab capable of simulating drug interactions with high accuracy, significantly speeding up drug discovery processes.

Our goal is to solve all diseases by leveraging AI to transform our understanding of biology and chemistry, enabling us to manipulate and craft solutions effectively.

AI can design affordable lab-ready antibiotics to fight the deadliest infections, which is a thrilling advancement for our future.

We aim to create a general drug design engine with AI that can be applied across various disease areas, not just targeting a single indication.

By 2028, I believe we'll have advanced AI systems capable of solving complex problems that humans can handle, thanks to significant ongoing work in AI development.

We're on the pathway to AI being able to design chips better than humans, which could eliminate bottlenecks in achieving greater intelligence.

The first generation of AI applications in drug design often focused on local models, but our approach is to build a more comprehensive system that can generalize across various tasks, as demonstrated by AlphaFold 3, which allows us to create models that generalize across chemistry and target space, enabling application to any protein or small molecule without needing fine-tuning.